At Centivax, we apply our computational immunoengineering expertise to develop superior therapeutic monoclonal antibodies against the most challenging targets. On March 30th, we completed optimization of a panel of ultra-potent neutralizing antibodies against SARS-CoV-2 (COVID-19).
https://www.centivax.com/